AS/Spondyloarthritis
Dr. John Cush RheumNow
3 years 10 months ago
Identifying Gaps in axSpA: Lessons from European Map of Axial Spondyloarthritis (EMAS)
Dr. Sheila Reyes, ( @RHEUMarampa) discusses the three interesting abstracts were presented by the group of Prof. Marco Garrido-Cumbrera on the EMAS at #ACR21.
https://t.co/Q50kEr5WEU https://t.co/5DScK5krtw
Dr. John Cush RheumNow
3 years 10 months ago
AxSpA: Geographic Prevalence Association with HLA-B27: Dr. Rachel Tate ( @uptoTate )
Dr. Rachel Tate discusses abstract #0368 presented at the #ACR21 annual meeting.
https://t.co/CnIjlWuKjZ https://t.co/vytIdK9CCo
PsA commonly affects peripheral joints. In up to a quarter of PsA patients, the spine may be involved and this is known as psoriatic spondylitis (PsSpA). An important research question is whether PsSpA and Axial Spondyloarthritis (AxSpA) with psoriasis are separate conditions or not.
JointHealth ACEJointHealth
3 years 10 months ago
Lianne Gensler presenting "Exercise Strategies for Ankylosing Spondylitis". Not all physical activity is similarly beneficial. Learn more now by attending her session at #ACR21!
@CherylKoehn @ArthritisNetwrk @EIM_Canada @exerciseworks @PhysioKTBroker @jwhittak_physio @JasminKMa https://t.co/rER3EdCohO
Dr. John Cush RheumNow
3 years 10 months ago
MRI Imaging in RA and SpA: Dr. Sheila Reyes ( @RHEUMarampa)
Dr. Sheila Reyes discusses abstracts #0468 and #0469, presented at the #ACR21 annual meeting.
https://t.co/MeVia60BNa https://t.co/WRgCifpioQ
CreakyJoints.org CreakyJoints
3 years 10 months ago
A study at #ACR21 by Charite-University Medicine Berlin researchers suggests taking tumor necrosis factor inhibitor (TNFi) #biologics earlier in the course of disease could slow down spinal progression in #AxialSpondyloarthritis patients. https://t.co/lDkaMkOcez
sheila RHEUMarampa
3 years 10 months ago
#Uveitis is the most ⬆ freq xtra-articular manifestation in axSpA.
What factors are assoc'd w/AAU attacks?
👁🗨Active disease
👁🗨History of AAU
Bottomline: Treat axSpA, treat uveitis = better outcomes.
@RheumNow #ACR21 abs1314 https://t.co/O0kHulwJoP
swethaann23 swethaann23
3 years 10 months ago
axSpA and Uveitis
Uveitis
🔼 in HLA-B27; Disease duration; Latin American pts
🔽 in Psoriasis
⭐️Uveitis was not significantly different in axSpA vs pSpA
Recurrent Uveitis
🔼disease duration and body mass index (BMI)
Abst #1307 #ACR21 @Rheumnow https://t.co/QDg8tOPgir
Differentiation between a flare of disease and infection in patients with autoinflammatory (AI) conditions, where fever is the hallmark, can be extremely difficult. Few studies have evaluated potential differentiators; and having such tools would meet a huge unmet need.
Dr. John Cush RheumNow
3 years 10 months ago
Emerging Therapies in Spondyloarthritis: A Promising Pipeline by Dr. Olga Petryna (@DrPetryna ) #ACR21
https://t.co/9ggUAh0YJe https://t.co/WHpQp3GYBe
Meral K. El Ramahi, MD MeralElRamahiMD
3 years 10 months ago
Knowledge Bowl at #ACR21
⭐️Which HLA allele confers an increased risk for anterior uveitis and inflammatory sacroillitis?
➡️HLA-B27
@RheumNow
Mrinalini Dey DrMiniDey
3 years 10 months ago
My summary article on some of the many abstracts at #ACR21 on #WorkParticipation in #axSpA.
Featured abstracts in this article:
#0358 https://t.co/LrZYWqCuOm
#0362 https://t.co/flL5MiqDL8
@RheumNow
https://t.co/tu5L0yIVIV
Richard Conway RichardPAConway
3 years 10 months ago
Dr Elliott presenting on US assessment of enthesitis with TNFi vs secukinumab. Surprisingly TNFi showed a more marked decrease in US enthesitis. Abstr#1356 #ACR21 @RheumNow https://t.co/XXgYMgkMyP
Poster Hall